pembrolizumab
merck
['melanoma', 'pembro']
incredible presentation of of s1801 trial about neoadjuvant vs adjuvant pembrolizumab. primary endpoint of event free survival is meet (72% vs 49%, hr .58, p .004) #esmo22 #melanoma 
Medical Oncologist. Melanoma and Skin Tumors. Early phase and phase III clinical trials. Hospital Clínic (Barcelona). Opinions are mine.